VALERA PHARMACEUTICALS RECEIVES MARKETING AUTHORIZATION IN DENMARK FOR VANTAS

A A

Valera Pharmaceuticals announced today that its subsidiary company, Valera Pharmaceuticals Ireland Limited, received marketing authorization from the Danish Medicines Agency for VANTAS(TM), its 12-month implant for the palliative treatment of advanced prostate cancer. VANTAS is currently marketed and sold in the United States by Valera. The U.S. Food and Drug Administration approved VANTAS for sale and distribution in October 2004.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051121005300&newsLang=en)